在葡萄糖转运体1型缺乏症 (G1D) 中,三类素与性饮食的结合
Adrian Avila1,2, Ignacio Málaga1,2, Deepa Sirsi2,3
1Rare Brain Disorders Program, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Mail Code 8813, Dallas, TX, 75390, USA.
Scientific reports
|June 2, 2023
概括
三平素是一种五碳燃料,可以是麻性,补充大脑的碳. 将其与性饮食相结合,对50%的葡萄糖载体1型缺乏症 (G1D) 患者来说是兼容的,为个性化治疗提供了信息.
科学领域:
- 生物化学 生物化学
- 神经科学是一个神经科学.
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 性饮食被用于神经系统疾病,但缺乏厌敏性能力,可能会限制治疗疗效.
- 在和痴呆症等疾病中,经常使用氧葡萄糖-正子发射断层扫描推断大脑中的碳耗尽.
- 补充性饮食所需的无性燃料是补充神经活动中丢失的碳,以补充性饮食.
研究的目的:
- 为了研究三类素的兼容性,五碳类的来源,与基因饮食在个人与葡萄糖载体1型缺乏症 (G1D).
- 评估三类素和性饮食成分之间的潜在相互作用,例如对新陈代谢的竞争或对症的影响.
主要方法:
- 十个患有G1D的个体在他们的最大可容忍剂量中与他们的性饮食一起接受了三氨酸.
- 监测了临床和脑电图分析,血糖和四和五碳症.
- 评估了β-基酸盐水平,以确定对症的影响.
主要成果:
- 在8名患有预先存在的症 (β-基酸盐>2mM) 的受试者中,有4名在服用三类胺后显著减少了症.
- 三类素和性饮食的组合被认为在50%具有显著基线症的个体中是兼容的.
- 测量参数的变化表明了两种治疗方法在参与者的子集之间的兼容性.
结论:
- 在患有G1D的个体中,类素可以与类饮食相兼容,特别是那些具有显著基线症的人.
- 这些发现支持针对神经疾病的性饮食的个性化性修饰的发展.
- 进一步对人类进行研究是必要的,以优化与性疗法结合的性燃料的使用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
241
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
241
Glucose Absorption Into the Small Intestine
31.8K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.8K
Glucose Transporters
23.6K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.6K
Oral Hypoglycemic Agents: Glinides
190
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
190
Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216


